Powered by

Caladrius Biosciences Reports Positive Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions

May 14, 2020 - Nasdaq
Financial Results

Single administration of CLBS16 durably improves heart function and symptoms in patients with coronary microvascular dysfunction BASKING RIDGE, N.J. , May 14, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, along with researchers from Cedars-Sinai ( Los Angeles ), Mayo Clinic ( Rochester, Minn. ) and ...